MX2016013341A - Agentes antiinflamatorios como compuestos virostaticos. - Google Patents
Agentes antiinflamatorios como compuestos virostaticos.Info
- Publication number
- MX2016013341A MX2016013341A MX2016013341A MX2016013341A MX2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A MX 2016013341 A MX2016013341 A MX 2016013341A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- compounds
- virostatic
- inflammatory agents
- hhv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general (I) y las sales y los derivados fisiológicamente funcionales de los mismos, (ver Fórmula) para usar en el tratamiento de enfermedades causadas por un adenovirus, el VHH (virus del herpes humano), VVZ (virus de la varicela zóster), VHS (virus del herpes simple), VEB (virus de Epstein-Barr), virus de vaccinia, o virus BK.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2014/057398 WO2015154820A1 (en) | 2014-04-11 | 2014-04-11 | Anti-inflammatory agents as virostatic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016013341A true MX2016013341A (es) | 2017-09-01 |
Family
ID=50483370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016013341A MX2016013341A (es) | 2014-04-11 | 2014-04-11 | Agentes antiinflamatorios como compuestos virostaticos. |
Country Status (8)
Country | Link |
---|---|
US (1) | US9795590B2 (es) |
JP (1) | JP6271806B2 (es) |
KR (1) | KR102265277B1 (es) |
AU (1) | AU2014390300A1 (es) |
CA (1) | CA2944570A1 (es) |
MX (1) | MX2016013341A (es) |
RU (1) | RU2016144238A (es) |
WO (1) | WO2015154820A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102312186B1 (ko) * | 2014-05-08 | 2021-10-14 | 판옵테스 파르마 게스.엠.베.하. | 안 질환 및 장애 치료용 화합물 |
TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
CN112996789A (zh) * | 2018-09-12 | 2021-06-18 | 诺华股份有限公司 | 抗病毒吡啶并吡嗪二酮化合物 |
CN109701024B (zh) * | 2019-03-04 | 2020-12-11 | 复旦大学 | Bk通道开放剂的新用途 |
AU2020353055B2 (en) | 2019-09-26 | 2024-03-07 | Gilead Sciences, Inc. | Antiviral pyrazolopyridinone compounds |
EP3892268B1 (en) * | 2020-04-10 | 2022-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of vidofludimus for the treatment of coronavirus infections |
US11376232B2 (en) | 2020-04-21 | 2022-07-05 | Immunic Ag | Vidofludimus for use in the treatment or prevention of viral diseases |
US20230355602A1 (en) * | 2020-08-31 | 2023-11-09 | Aslan Pharmaceuticals Pte Ltd | Treatment and/or prevention of a viral infection |
WO2022196236A1 (ja) * | 2021-03-18 | 2022-09-22 | 国立大学法人 鹿児島大学 | 抗薬剤耐性インフルエンザウイルス剤及び抗薬剤耐性インフルエンザウイルス剤の製造のための化合物の使用 |
AU2022253683A1 (en) | 2021-04-09 | 2023-10-26 | Immunic Ag | Deuterated dhodh inhibitors |
CA3240950A1 (en) | 2021-12-23 | 2023-06-29 | Christian Gege | Dhodh inhibitors containing a carboxylic acid bioisostere |
US20230278979A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
WO2023172818A1 (en) * | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
WO2023232884A1 (en) | 2022-06-01 | 2023-12-07 | Immunic Ag | Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
AU2003300530A1 (en) | 2002-12-23 | 2004-07-14 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
RU2367650C2 (ru) * | 2002-12-23 | 2009-09-20 | 4Ск Аг | Циклоалкендикарбоновые кислоты как противовоспалительные, иммуномодулирующие и антипролиферативные средства |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
TWI530286B (zh) | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
-
2014
- 2014-04-11 US US15/302,164 patent/US9795590B2/en active Active
- 2014-04-11 KR KR1020167031531A patent/KR102265277B1/ko active IP Right Grant
- 2014-04-11 JP JP2017504237A patent/JP6271806B2/ja active Active
- 2014-04-11 AU AU2014390300A patent/AU2014390300A1/en not_active Abandoned
- 2014-04-11 MX MX2016013341A patent/MX2016013341A/es unknown
- 2014-04-11 RU RU2016144238A patent/RU2016144238A/ru not_active Application Discontinuation
- 2014-04-11 CA CA2944570A patent/CA2944570A1/en not_active Abandoned
- 2014-04-11 WO PCT/EP2014/057398 patent/WO2015154820A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR20160136453A (ko) | 2016-11-29 |
KR102265277B1 (ko) | 2021-06-16 |
RU2016144238A3 (es) | 2018-05-11 |
RU2016144238A (ru) | 2018-05-11 |
CA2944570A1 (en) | 2015-10-15 |
JP2017513935A (ja) | 2017-06-01 |
JP6271806B2 (ja) | 2018-01-31 |
US9795590B2 (en) | 2017-10-24 |
WO2015154820A1 (en) | 2015-10-15 |
AU2014390300A1 (en) | 2016-10-20 |
US20170027905A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016013341A (es) | Agentes antiinflamatorios como compuestos virostaticos. | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
EP3774775C0 (en) | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNO DEFICIENCY VIRUS REPLICATION | |
EA201790921A1 (ru) | Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr | |
BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
MX2014005304A (es) | Biaril eter sulfonamidas y su uso como agentes terapeuticos. | |
NZ711896A (en) | Compounds and methods for kinase modulation, and indications therefor | |
PH12015500274A1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
IN2014CN03337A (es) | ||
BR112017006073A2 (pt) | derivado de ácido 4-(4-(4-fenilureído-naftalen-1-il)óxi-piridin-2-il)amino-benzoico como inibidor de quinase de p38 | |
PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
ES2529143R1 (es) | Combinacion de al menos dos agentes antivirales de accion directa, ribavirina pero no interferon para uso de tratamiento del vhc | |
EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
MX364486B (es) | Derivados de piridazinona-amidas. | |
NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
MX352564B (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
MX368162B (es) | Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr). | |
CO7131375A2 (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
BR112017007715A2 (pt) | derivados de tienopirimidina como inibidores de nik | |
IN2014MN02056A (es) | ||
MX341728B (es) | Derivados sulfonamido de 3, 4/diarilpirazoles como inhibidores de proteina quinasa. | |
AU2015295120A8 (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
MX340622B (es) | Formulaciones antivirales topicas para prevencion de transmision de hsv-2. |